

Org #556966-4955  
Date: July 5, 2021

## **Elicera Therapeutics' board and management buy shares**

**Gothenburg, July 5, 2021 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immunooncological treatments focusing on CAR T-cells and oncolytic viruses, announced today that the board and management have bought shares in the company.**

### **Purchase of shares**

Eight people on the board and management have bought a total of 132,591 shares in Elicera outside the market. Those who bought shares include the chairman of the board, the CEO, the CSO and the CFO.

### **For further information please contact:**

Jamal El-Mosleh, CEO, Elicera Therapeutics AB  
Phone: +46 (0) 703 31 90 51  
[jamal.elmosleh@elicera.com](mailto:jamal.elmosleh@elicera.com)

### **About Elicera Therapeutics AB**

Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses. In addition, Elicera has developed a technology platform called iTANK that can be used to optimize all CAR T cells in development and activate killer T cells against cancer. The Company's share (ELIC) is traded on Nasdaq First North Growth Market. G&W Fondkommission has been appointed the Company's Certified Adviser. E-mail: [ca@gwkapital.se](mailto:ca@gwkapital.se), tel: +468-503 000 50.

For more information, please visit [www.elicera.com](http://www.elicera.com)